<DOC>
	<DOCNO>NCT00759135</DOCNO>
	<brief_summary>This complete study evaluate safety efficacy two dose level NX-1207 treatment BPH ( benign prostatic hyperplasia ) versus finasteride .</brief_summary>
	<brief_title>Phase 2 Study NX-1207 Treatment Benign Prostatic Hyperplasia ( BPH ) ( Enlarged Prostate )</brief_title>
	<detailed_description>Subjects randomize NX-1207 blind dose level NX-1207 receive .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Documented history BPH least 1 year 2 . AUA SI ≥ 15 3 . Prostate Volume ≥ 30 mL ≤ 70 mL 4 . Qmax &lt; 15 mL/sec 1 . History illness condition may interfere study endanger subject 2 . Use prescribed medication may interfere study endanger subject 3 . Presence median lobe prostate 4 . Surgery MIST previous 12 month treatment BPH 5 . Postvoid residual urine volume &gt; 350 mL 6 . PSA ≥ 10 ng/mL ; prostate cancer must rule PSA ≥ 4 ng/mL</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged Prostate</keyword>
</DOC>